PPARG and diabetes mellitus: We previously reported changes in HDL and LDL subclasses distribution in diabetes patients treated with a PPARγ agonist [31], thereby supporting the presumption that PUFAs could affect lipoproteins’ structure and functionality by acting as PPAR ligands.